• 03 October 2019
  • 2 min read

Three pharmaceutical companies accused of collusion over NHS drug supply

  • Nurses news
    Nurses.co.uk editorial team
  • 0
  • 1057

Three drug firms have been found provisionally guilty by the competition watchdog of colluding over the supply of a life-saving treatment for thousands of patients on the NHS.

Protecting monopoly

The Competition and Markets Authority (CMA) said it believes pharmaceutical firm Aspen paid two rivals – Amilco and Tiofarma – to stay out of the market for fludrocortisone acetate tablets – a treatment for Addison’s disease.

Aspen’s actions protected its UK monopoly over the supply of the drug to the NHS and gave the firm the opportunity to increase prices by up to 1,800%, the CMA said.

In exchange, it is alleged that Tiofarma was made the sole manufacturer of fludrocortisone for direct sale in the UK, and Amilco received a 30% share of the increased prices that Aspen was able to charge.

Find Your Next Job on Nurses.co.uk

1000s of UK Nursing and Care Home Jobs. Updated all day, every day.

Find your next Job!

Aspen settles for £8m

Aspen has admitted its part in the collusion and will pay £8 million to the NHS as part of a settlement, as well as up to a further £2.1 million if the CMA ultimately concludes competition law has been broken.

It marks the first time a CMA probe has secured a payment to the NHS.

Aspen has also committed to ensure there will be at least two suppliers of fludrocortisone in the UK to help the NHS access more competitive prices.

But Amilco and Tiofarma have yet to admit their part in the alleged illegal market-sharing.

They now have the opportunity to respond to the CMA’s provisional findings.

NHS should not be denied choice

Michael Grenfell, the CMA’s executive director of enforcement, said: “The NHS should not be denied the opportunity of benefiting from an increased choice of suppliers, and so potential savings on what it spends on essential drugs.

“This highlights the importance of competition in making sure the NHS, and so ultimately UK taxpayers, do not pay more than they should for medicines.”

Fludrocortisone is a vital treatment, on which thousands of patients depend, mainly to treat primary or secondary adrenal insufficiency, commonly known as Addison’s disease.

Aspen is a South African pharmaceutical firm, while Amilco is a British company that provides consultancy services to drug companies, and Tiofarma is a Dutch pharmaceutical manufacturer that makes products including fludrocortisone acetate.

Related stories

Pharmacists experiencing shortages of every major type of medicine according to a poll

National Audit Office warns of ‘risks’ to medical supplies from no-deal Brexit

NHS experts sent into care homes to tackle over-medication

Like this article? Subscribe to the Nurses.co.uk Weekly!

Care Professionals Helping One Another

Nurses.co.uk is a community where people like you can contribute and share advice. Learn & never miss out on updates. Subscribe to support our mission.

  • Nurses news
    Nurses.co.uk editorial team

About the author

  • Nurses news
    Nurses.co.uk editorial team

Bringing you a daily update of nursing, NHS, health and social care news from around the UK.

Want to get involved in the discussion
Sign In Join